Being exposed to tenofovir before birth appears to have no adverse effects on babies born to HIV-positive mothers in Africa, a recent study reports.
Most of the women who became pregnant were taking a combo containing tenofovir before and throughout their pregnancies and there was no increase in birth defects, growth abnormalities or kidney problems. Furthermore, none tested for HIV were positive, and no bone fractures or kidney problems occurred during follow-up and there was no effect on growth at two years. Babies were followed for up to four years.
Their findings suggest that tenofovir containing ART is a reasonable choice in pregnancy and that tenofovir pre-exposure prophylaxis (PrEP) is also a reasonable choice for women who are at high risk of seroconverting during pregnancy.